In my previous article I outlined reasons Rockwell Medical (RMTI) was worth considering as a speculative investment. Since then, Rockwell's risk could decrease significantly if the CMS approves a separate J-code for powdered Triferic as announced. If approved, dialysis centers - that are profit driven - will likely use Triferic in place of erythropoiesis-stimulating agents ((ESA)). Rockwell also plans to file a NDA for intravenous Triferic during first-half 2019 with possible FDA approval in early 2020. If these scenarios plays out, revenues from Triferic should making Rockwell a good long-term investment.
Triferic's potential